A phase 2 multicenter clinical trial has demonstrated that rogaratinib, an FGFR inhibitor, effectively targets SDH-deficient gastrointestinal stromal tumors (GIST)—a particularly aggressive subset that has proven resistant to standard therapies. Published in Nature Medicine, this research represents a significant advancement in precision oncology, marking the first successful targeting of epigenetic oncogene activation mechanisms in this patient population. SDH-deficient GIST tumors lack functional succinate dehydrogenase enzymes, rendering conventional tyrosine kinase inhibitors like imatinib largely ineffective. Rogaratinib works by inhibiting the hyperactive FGFR signaling pathways characteristic of these tumors, providing a targeted approach for patients with limited treatment options. While FGFR inhibitors have been previously approved for other cancer types, this trial represents their first validated application in SDH-deficient GIST, offering encouragement for a historically difficult-to-treat population.
Was this article helpful?
